Dr. Michael Keng
Claim this profileUniversity of Virginia Cancer Center
Area of expertise
Acute Myelogenous Leukemia
Michael Keng has run 8 trials for Acute Myelogenous Leukemia.
Acute Myeloid Leukemia
Michael Keng has run 8 trials for Acute Myeloid Leukemia. Some of their research focus areas include:
Affiliated Hospitals
University Of Virginia Cancer Center
University Of Virginia
Clinical Trials Michael Keng is currently running
DFP-10917
for Acute Myeloid Leukemia
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), depending on the patient's prior induction treatment.
Recruiting
2 awards
Phase 3
4 criteria
DFP-10917 + Venetoclax
for Acute Myeloid Leukemia
This Phase I/II trial evaluates the safety and preliminary efficacy of DFP-10917 combined with venetoclax in relapsed or refractory acute myeloid leukemia. DFP-10917 is given as a 14-day continuous IV infusion every 28 days, alongside a 14-day oral course of venetoclax following an initial dose ramp-up. The initial phase tests a starting dose of 4 mg/m²/day of DFP-10917 with 400 mg daily of venetoclax. The Data Monitoring Committee reviews toxicity after one treatment cycle. If DLTs are minimal, more patients are added to confirm safety. If the lower dose level shows tolerability, it proceeds to the Phase II expansion to assess the treatment's effectiveness against leukemia using a Simon's two-stage design, targeting up to 17 participants.
Recruiting
1 award
Phase 1 & 2
4 criteria
More about Michael Keng
Clinical Trial Related
6 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Michael Keng has experience with
- Venetoclax
- DFP-10917
- Azacitidine
- Etoposide
- Fludarabine
- CPI-613
Breakdown of trials Michael Keng has run
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Keng specialize in?
Michael Keng focuses on Acute Myelogenous Leukemia and Acute Myeloid Leukemia. In particular, much of their work with Acute Myelogenous Leukemia has involved treating patients, or patients who are undergoing treatment.
Is Michael Keng currently recruiting for clinical trials?
Yes, Michael Keng is currently recruiting for 3 clinical trials in Charlottesville Virginia. If you're interested in participating, you should apply.
Are there any treatments that Michael Keng has studied deeply?
Yes, Michael Keng has studied treatments such as Venetoclax, DFP-10917, Azacitidine.
What is the best way to schedule an appointment with Michael Keng?
Apply for one of the trials that Michael Keng is conducting.
What is the office address of Michael Keng?
The office of Michael Keng is located at: University of Virginia Cancer Center, Charlottesville, Virginia 22903 United States. This is the address for their practice at the University of Virginia Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.